Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N, WKN: A422EZ), a developer of an AI-powered platform for real-world applications across multiple critical industries, has been named a co-applicant in a competitive Terry Fox Research Institute grant awarded to advance Onco-Innovations Limited’s SynoGraph™ oncology platform. The collaboration, announced on September 22, also includes the Michael Smith Genome Sciences Centre and the Centre de recherche du CHU de Québec-Université Laval as co-applicants, with Onco-Innovations serving as lead applicant. The project, titled “Causal AI to Predict First-in-Human Clinical Outcomes from Preclinical and Real-World Clinico-Genomic Data,” seeks to determine whether causal AI can improve predictions of first-in-human clinical outcomes, a critical step in accelerating drug development and reducing costly late-stage failures.
Redwood AI will contribute proprietary data integration and physicochemical modelling methods to expand SynoGraph’s predictive capabilities. The grant supports a project with an estimated budget of $3.5 million and reimburses eligible costs up to 25% of that amount. Academic partners will provide clinico-genomic and imaging data for research using federated learning, which is intended to support analysis while protecting data privacy. For Redwood AI, this collaboration represents a strategic expansion into the oncology space, leveraging its expertise in AI-driven data integration and chemical modelling to address one of the most challenging problems in pharmaceutical development: predicting how experimental therapies will perform in humans.
The involvement of the Terry Fox Research Institute, a leading Canadian cancer research organization, underscores the scientific merit of the project. If successful, the use of causal AI in this context could transform how preclinical data is translated into clinical trials, potentially shortening timelines and increasing success rates. This is particularly important given the high attrition rates in oncology drug development, where many promising candidates fail in early-phase trials. By improving the accuracy of first-in-human outcome predictions, the project could reduce risks for drug developers and ultimately bring effective treatments to patients faster.
Redwood AI’s participation also highlights the growing trend of public-private partnerships in AI research, where academic institutions provide data and domain expertise while industry partners contribute technological capabilities. The federated learning approach ensures that sensitive patient data remains protected, addressing privacy concerns that often hinder collaborative research. For investors, this news signals Redwood AI’s ability to secure competitive grant funding and collaborate with top-tier research institutions, potentially opening doors to further opportunities in the healthcare sector. The company’s newsroom at https://ibn.fm/RDWCF offers ongoing updates.
As AI continues to permeate various industries, Redwood AI’s involvement in this Terry Fox-funded project positions it at the intersection of AI and oncology, a field with significant unmet needs. The project’s focus on causal AI, which goes beyond correlation to understand cause-and-effect relationships, could provide deeper insights into disease mechanisms and treatment responses. This aligns with broader efforts to harness AI for precision medicine, where therapies are tailored to individual patients based on their genetic and clinical profiles. Success in this project could lead to broader applications of Redwood AI’s technology in other therapeutic areas, further validating its platform.
The announcement was disseminated through AINewsWire, a specialized communications platform focused on AI advancements, which is part of the Dynamic Brand Portfolio at IBN. IBN provides InvestorWire for wire distribution, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit www.AINewsWire.com. The full terms of use and disclaimers are available at https://www.AINewsWire.com/Disclaimer.
